CIZ.LSE Cizzle Biotechnology Holdings PLC

Healthcare Biotechnology London Exchange
0.0114 GBX
Close of Nov 3, 2026
0.9000 3.90
Market cap
GBX 4.84M
P/E
-
P/B
70.09x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is CIZ.LSE undervalued?

Graham number

The Graham number of Cizzle Biotechnology Holdings PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cizzle Biotechnology Holdings PLC fundamental analysis

No fundamental analysis for Cizzle Biotechnology Holdings PLC yet.

Cizzle Biotechnology Holdings PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cizzle Biotechnology Holdings PLC

Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood immunoassay test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.

Full company profile